Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.
  1. Home
  2. Publications
  3. Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.

Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.

Authors:
  • PRPauline Rivière
    Pauline Rivière
  • CKCaitlyn Kanters
    Caitlyn Kanters
  • ANAlexander Ni
    Alexander Ni
  • GPGauthier Pellet
    Gauthier Pellet
  • MHMarianne Hupé
    Marianne Hupé
  • NANesrine Aboulhamid
    Nesrine Aboulhamid
  • FPFlorian Poullenot
    Florian Poullenot
  • ABAlain Bitton
    Alain Bitton
  • FZFrank Zerbib
    Frank Zerbib
  • Peter L. Lakatos
    Peter L. Lakatos
  • WAWaqqas Afif
    Waqqas Afif
  • DLDavid Laharie
    David Laharie

Publisher website
Google Scholar
  • 16 June 2022
    • journal article
    • abstracts
    • Published by Elsevier in Gastroenterology
    • Vol. 162  (7)
    • DOI:10.1016/s0016-5085(22)61914-0
Abstract
No abstract available
Keywords
  • USTEKINUMAB
  • CENTER (CATEGORY THEORY)
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.